The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia

Hiroshima Journal of Medical Sciences

Volumn 61, Issue 4, 2012, Pages 75-83

  Sato, Goro ^a,c   Yoshimura, Shinpei ^b   Yamashita, Hidehisa ^b   Okamoto, Yasumasa ^b   Yamawaki, Shigeto ^b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Kusatsu Hospital   (Japan)

Author keywords

Aripiprazole; Neurocognitive functioning; Randomized crossover trial; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; VITAL SIGN;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA;

EID: 84872535465     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. Fourth ed. (DSM-IV). American Psychiatric Press, Washington D. C.
2. Anghelescu, I. and Wolf, J. 2004. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. J. Clin. Psychiatry 65: 1286-1287.
3. Ben-Jonathan, N. and Hnasko, R. 2001. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 22: 724-763. (Pubitemid 34214293)
4. Bilder, R.M., Goldman, R.S., Robinson, D., Reiter, G., Bell, L., Bates, J.A., Pappadopulos, E., Willson, D.F., Alvir, J.M., Woerner, M.G., Geisler, S., Kane, J.M. and Lieberman, J.A. 2000. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157: 549-559. (Pubitemid 30191193)
5. Brekke, J.S., Raine, A., Ansel, M., Lencz, T. and Bird, L. 1997. Neuropsychological and psychophysiological correlates of psychosocial functioning in schizophrenia. Schizophr. Bull. 23: 19-28. (Pubitemid 27087904)
6. Burris, K.D., Molski, T.F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F.D. and Molinoff, P.B. 2002. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302: 381-389. (Pubitemid 34680462)
7. Buysse, D.J., Reynolds, C.F. 3rd, Monk, T.H., Berman, S.R. and Kupfer, D.J. 1989. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 28: 193-213. (Pubitemid 19144991)
8. Chan, H.Y., Lin, W.W., Lin, S.K., Hwang, T.J., Su, T.P., Chiang, S.C. and Hwu, H.G. 2007. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J. Clin. Psychiatry 68: 29-36.
9. Chrzanowski, W.K., Marcus, R.N., Torbeyns, A., Nyilas, M. and McQuade, R.D. 2006. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl). 189: 259-266. (Pubitemid 44691547)
10. David, A., Buchanan, A., Reed, A. and Almeida, O. 1992. The assessment of insight in psychosis. Br. J. Psychiatry 161: 599-602.
11. El-Sayeh, H.G., Morganti, C. and Adams, C.E. 2006. Aripiprazole for schizophrenia. Systematic review. Br. J. Psychiatry 189: 102-108.
12. Elfgren, C.I. and Risberg, J. 1998. Lateralized frontal blood flow increases during fluency tasks: influence of cognitive strategy. Neuropsychologia. 36: 505-512. (Pubitemid 28342186)
13. Farwell, W.R., Stump, T.E., Wang, J., Tafesse, E., L'Italien, G. and Tierney, W.M. 2004. Weight gain and new onset diabetes associated with olanzapine and risperidone. J. Gen. Intern Med. 19: 1200-1205. (Pubitemid 40041384)
14. Gold, J.M. 2004.Cognitive deficits as treatment targets in schizophrenia. Schizophr. Res. 72: 21-28. (Pubitemid 39452902)
15. Gold, J.M. and Harvey, P.D. 1993. Cognitive deficits in schizophrenia. Psychiatr. Clin. North Am. 16: 295-312. (Pubitemid 23174755)
16. Goldberg, T.E. and Weinberger, D.R. 1988. Probing prefrontal function in schizophrenia with neuropsychological paradigms. Schizophr Bull. 14: 179-183.
17. Goodnick, P.J., Rodriguez, L. and Santana, O. 2002. Antipsychotics: impact on prolactin levels. Expert Opin. Pharmacother. 3: 1381-1391.
18. Grant, D.A. and Berg, E.A. 1948. A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card sorting problem. J. Exp. Psychol. 38: 404-411.
19. Green, M.F. 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry. 153: 321-330. (Pubitemid 26074706)
20. Grunder, G., Carlsson, A. and Wong, D.F. 2003. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch. Gen. Psychiatry 60: 974-977. (Pubitemid 37222078)
21. Harvey, P.D., Howanitz, E., Parrella, M., White, L., Davidson, M., Mohs, R.C., Hoblyn, J. and Davis, K.L. 1998. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am. J. Psychiatry 155: 1080-1086. (Pubitemid 28357734)
22. Hirose, T. and Kikuchi, T. 2005. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J. Med. Invest. 52 Suppl: 284-290. (Pubitemid 43051889)
23. Hogan, T.P., Awad, A.G. and Eastwood, R. 1983. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 13: 177-183. (Pubitemid 13132147)
24. Hunter, R.H., Joy, C.B., Kennedy, E., Gilbody, S.M. and Song, F. 2003. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev. CD000440.
25. Inada, T. and Yagi, G. 1995. Current topics in tardive dyskinesia in Japan. Psychiatry Clin. Neurosci. 49: 239-244. (Pubitemid 26020606)
26. Jenkinson, C., Coulter, A. and Wright, L. 1993. Short form 36 (SF36) health survey questionnaire: normative data for adults of working age. BMJ. 306: 1437-1440. (Pubitemid 23154745)
27. Johns, M.W. 1991. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14: 540-545.
28. Johnsen, E. and Jørgensen, H.A. 2008. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 8: 31.
29. Kasper, S., Lerman, M.N., McQuade, R.D., Saha, A., Carson, W.H., Ali, M., Archibald, D., Ingenito, G., Marcus, R. and Pigott, T. 2003. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int. J. Neuropsychopharmacol. 6: 325-337. (Pubitemid 38146250)
30. Kay, S.R., Fiszbein, A. and Opler, L.A. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13: 261-276. (Pubitemid 18039085)
31. Kern, R.S., Green, M.F., Cornblatt, B.A., Owen, J.R., McQuade, R.D., Carson, W.H., AH, M. and Marcus, R. 2006. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 187: 312-320. (Pubitemid 44079923)
32. Kapur, S., Zipursky, R.B. and Remington, G. 1999. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156: 286-293. (Pubitemid 29077120)
33. Lee, B.H., Kim, Y.K. and Park, S.H. 2006. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol. Psychiatry 30: 714-717.
34. Maeshima, S., Funahashi, K., Itakura, T., Komai, N. and Dohi, N. 1994. Computed topographic electroencephalographic study in left hemiplegic patients with higher cortical dysfunction. Arch. Phys. Med. Rehabil. 75: 189-192. (Pubitemid 24061493)
35. Marder, S.R. and Meibach, R.C. 1994. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry 151: 825-835.
36. Naber, D. and Lambert, M. 2004. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog. Neuropsychopharmacol Biol. Psychiatry 28: 1213-1219. (Pubitemid 39592919)
37. Nuechterlein, K.H. and Dawson, M.E. 1984. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 10: 160-203.
38. Palmer, B.W., Heaton, R.K., Paulsen, J.S., Kuck, J., Braff, D., Harris, M.J., Zisook, S. and Jeste, D.V. 1997. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 11: 437-446. (Pubitemid 27294667)
39. Pattij, T. and Vanderschuren, L.J. 2008. The neuropharmacology of impulsive behaviour. Trends Pharmacol. Sci. 29: 192-199.
40. Potkin, S.G., Saha, A.R., Kujawa, M.J., Carson, W.H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G. and Marder, S.R. 2003. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60: 681-690. (Pubitemid 36818630)
41. Ramaswamy, S., Vijay, D., William, M., Sattar, S.P., Praveen, F. and Petty, F. 2004. Aripiprazole possibly worsens psychosis. Int. Clin. Psychopharmacol. 19: 45-48. (Pubitemid 38114625)
42. Reeves, R.R. and Mack, J.E. 2004. Worsening schizoaffective disorder with aripiprazole. Am. J. Psychiatry 161: 1308.
43. Reitan, R.M. 1958. Validity of the Trail Making Test as an indication of organic brain damage. Perceptual and motor skills 8: 271-276.
44. Saykin, A.J., Gur, R.C., Gur, R.E., Mozley, P.D., Mozley, L.H., Resnick, S.M., Rester, D.B. and Stafiniak, P. 1991. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch. Gen. Psychiatry 48: 618-624.
45. Stroop, J.R. 1935. Studies of interference in serial verbal reactions. J. Exp. Psychol. 18: 643-662.
46. Suhara, T., Okubo, Y., Yasuno, F., Sudo, Y., Inoue, M., Ichimiya, T., Nakashima, Y., Nakayama, K., Tanada, S. and Suzuki, K. 2002. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry 59: 25-30. (Pubitemid 34044401)
47. Suhara, T., Yasuno, F., Sudo, Y., Yamamoto, M., Inoue, M., Okubo, Y. and Suzuki, K. 2001. Dopamine D2 receptors in the insular cortex and the personality trait of novelty seeking. Neuroimage 13: 891-895. (Pubitemid 32848333)
48. Umbricht, D. and Kane, J.M. 1995. Risperidone: efficacy and safety. Schizophr Bull. 21: 593-606.
49. Velligan, D.I. and Bow-Thomas, C.C. 1999. Executive function in schizophrenia. Semin. Clin. Neuropsychiatry 4: 24-33.
50. Velligan, D.I., Ritch, J.L., Sui, D., DiCocco, M. and Huntzinger, C.D. 2002. Frontal Systems Behavior Scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function. Psychiatry Res. 113: 227-236. (Pubitemid 36136045)
51. Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.P., Citrome, L., McEvoy, J.P., Cooper, T.B., Chakos, M. and Lieberman, J.A. 2002. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am. J. Psychiatry. 159: 255-262. (Pubitemid 34126903)
52. Wahl, R. and Ostroff, R. 2005. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am. J. Psychiatry 162: 1542-1543.
53. Wechsler, D. 1981. Wechsler Adult Intelligence Scale-Revised. Psychological Corp. New York.
54. Yamashita, H., Mori, K., Nagao, M., Okamoto, Y., Morinobu, S. and Yamawaki, S. 2004. Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population. J. Clin. Psychiatry 65: 1525-1530.
55. Young, R.M., Lawford, B.R., Barnes, M., Burton, S.C., Ritchie, T., Ward, W.K. and Noble, E.P. 2004. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br. J. Psychiatry 185: 147-151. (Pubitemid 39061458)